SCHEMBL4170820

SCHEMBL4170820

Cc1cc2[nH]c(Nc3ccc(Oc4ccncc4)cc3)nc2cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.59
RAF1 P04049 6/20 0.50
CSNK1D P48730 4/20 0.47
CSNK1A1 P48729 3/20 0.47
CSNK1G2 P78368 3/20 0.45
BRAF P15056 5/20 0.44
PDE10A Q9Y233 3/20 0.44
GSK3B P49841 2/20 0.42
POLB P06746 1/20 0.40
TEK Q02763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164559 0.90 KDR (0.63) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4164763 0.90 KDR (0.54) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4173092 0.88 CSNK1D (0.48) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4167621 0.83 KDR (0.76) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4161669 0.82 KDR (0.56) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4158747 0.82 KDR (0.59) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4164725 0.78 CSNK1A1 (0.52) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4173611 0.78 CSNK1D (0.52) KDRRAF1CSNK1DCSNK1A1CSNK1G2
SCHEMBL4161807 0.78 KDR (0.52) KDRRAF1CSNK1DCSNK1A1BRAF
SCHEMBL13906245 0.77 KDR (0.59) KDRRAF1CSNK1DCSNK1A1CSNK1G2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082404-A1 BENZIMIDAZOLES MERCK PATENT GMBH (DE) 2009-03-26 US claimed
US-20070066660-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-03-22 US claimed
US-20090082404-A1 BENZIMIDAZOLES MERCK PATENT GMBH (DE) 2009-03-26 US disclosed
US-20090082404-A1 BENZIMIDAZOLES MERCK PATENT GMBH (DE) 2009-03-26 US disclosed
US-20090082404-A1 BENZIMIDAZOLES MERCK PATENT GMBH (DE) 2009-03-26 US disclosed
US-7470702-B2 Benzimidazoles MERCK PATENT GMBH (DE) 2008-12-30 US disclosed
US-7470702-B2 Benzimidazoles MERCK PATENT GMBH (DE) 2008-12-30 US disclosed
US-7470702-B2 Benzimidazoles MERCK PATENT GMBH (DE) 2008-12-30 US disclosed
US-20070066660-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-03-22 US disclosed
US-20070066660-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-03-22 US disclosed
US-20070066660-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082404-A1 BENZIMIDAZOLES TIE1, KDR, FLT1 KDR 2/4885RAF1 765/4885CSNK1D 1595/4885
US-20070066660-A1 Benzimidazolyl derivatives TIE1, ECE2, ABL1 KDR 5/4885RAF1 80/4885CSNK1D 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.